1. Clinical & Scientific Overview
Misoprostol (PGE1 Analogue — Obstetric & GI Ulcer Protocol) (TIP-MED-000246, Reference Code [12.14]) is classified under
Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a Synthetic Prostaglandin E1 Analogue (Oxytocic / Cervical Ripening Agent & Mucosal Cytoprotective).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.14], p. 161): Misoprost, Cytolog, Kontrac — Strengths & Dosage Forms: Tablet: 25 mcg, 100 mcg, 200 mcg.
Tablet: 25 mcg, 100 mcg, 200 mcg.
3. Mechanism of Action & Pharmacodynamics
Binds myometrial EP2/EP3 prostaglandin receptors -> induces rhythmic uterine smooth muscle contractions and collagenase-mediated cervical softening.
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention and treatment of postpartum haemorrhage (PPH)
- medical termination of pregnancy (sequentially with Mifepristone under MTP Act)
- management of missed/incomplete miscarriage
- cervical ripening
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: PPH Prevention: 600 mcg PO single dose after delivery; PPH Treatment: 800 mcg sublingually single dose. Early Medical Termination (<7-9 wk, 36-48h after Mifepristone 200 mg): 800 mcg vaginal/buccal/sublingual. Labour Induction (live fetus): ONLY 25 mcg q4-6h under strict obstetric monitoring. • Paediatric: Not applicable.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No routine adjustment required for single/short obstetric protocols. • Hepatic: Use with caution in severe hepatic disease.
Renal: No routine adjustment required for single/short obstetric protocols. • Hepatic: Use with caution in severe hepatic disease.
Renal: No routine adjustment required for single/short obstetric protocols. • Hepatic: Use with caution in severe hepatic disease.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Confirmed or suspected ectopic pregnancy; previous caesarean scar or major uterine surgery when used for 2nd/3rd-trimester induction (high risk of uterine rupture); ongoing desired pregnancy (Moebius syndrome teratogen). • Precautions: STRICT REGULATORY CONTROL IN INDIA (MTP Act & PCPNDT/CDSCO rules): Must ONLY be dispensed against a valid prescription from a registered obstetrician/gynaecologist (RMP) or supplied directly to approved MTP centres; 25 mcg tablet is for term induction, whereas 200 mcg tablet is for PPH/MTP—using 200 mcg in a term pregnant uterus causes fetal asphyxia and uterine rupture!
Key Clinical Precautions: Renal: No routine adjustment required for single/short obstetric protocols. • Hepatic: Use with caution in severe hepatic disease.
8. Adverse Effects Profile
- Shivering, transient pyrexia (38-40°C via hypothalamic PGE reset—responds to paracetamol, does not always indicate sepsis), uterine cramping, diarrhoea, nausea.
- Uterine tachysystole, uterine rupture, amniotic fluid embolism, incomplete abortion with heavy bleeding.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Oxytocin -> Wait at least 4 hours after the last dose of Misoprostol before starting IV Oxytocin infusion (synergistic uterine hyperstimulation/rupture); Magnesium-containing antacids -> worsen misoprostol-induced diarrhoea
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Chills and fever within 1-2 hours of taking Misoprostol are common drug effects; seek emergency hospital care if bleeding soaks >2 thick pads per hour for 2 consecutive hours.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 25 mcg, 100 mcg, 200 mcg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.14] (p. 161)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.15] Mifepristone (Antiprogestogen — Medical Termination Combi-Pack) — Synthetic Steroidal Antiprogestogen & Antiglucocorticoid (Progest
- [12.16] Magnesium Sulphate Injection (Parenteral IV/IM Pritchard & Zuspan Eclampsia Regimen) — Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher &
- [12.17] Oxytocin, Methylergometrine Maleate & Carboprost — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot
- [12.16]-CMP163 Isoxsuprine Hydrochloride IP — Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher &